Why Wall Street Cools on Merck Stock Despite Cancer Vaccine Success

New York, Friday, 21 August 2026.
RBC Capital downgraded Merck to Sector Perform following a steep stock rally, warning that its $150 valuation is unprecedented ahead of Keytruda’s $30 billion patent loss in 2028.